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Investigation of  the underlying mechanism leading to inter- and intrasubject variations in ttle 
plasma concentration-time profiles of drugs (1) can considerably benefit rational drug therapy. 
The significant effect of  gastric empO,ing on tile rate and extent of celiprolol absorption and its 
role with respect to double-peak formation was demonstrated in tire present study. In four dogs 
racemic celiprolol was dosed perorally in a crossover design during four different phases of tile 
fasted-state gastric cycle and gastric motility was recorded simultaneously using a manometric 
measurement system. Intravenous doses were also given to obtain disposition and bioavailability 
parameters. Tire blood samples were assayed by a stereoselective HPLC method (2). The time 
to onset of the active phase of the gastric cycle showed an excellent correlation with the time to 
celiprolol peak concentration. Furthermore, bioavailability was increased when celiprolol was 
administered during the active phase. Double peaks were observed when the first active phase was 
relatively short, suggesting that a portion of the drug remained in the stomach until the next 
active phase. Population pbarmacokinetic modeling of the data with a two-compartment open 
model with two lag times incorporating the motility data confirmed the effect of time to gastric 
emptying on the variability of  the oral pharmacokinetics of celiprolol. Tire fasted-state motility 
phases determine the rate and extent of celiprolol absorption and influence the occurrence of 
double peaks. Peak plasma levels of celiprolol exhibit less variability if lag times, and therefore 
gastric emptying times, are taken into consideration. 
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INTRODUCTION 
Celiprolol, 3-[3-acetyl-4-[3-t- (butyl-amino)-2-hydroxy-propoxy]-phenyl]- 
l,l-diethylurea hydrochloride (MW 414 g/mol), is a hydrophilic ~-adreno- 
ceptor antagonist with a pka of 9.7. It is highly soluble in water (176 mg/ml) 
and the logarithm of the octanol/water partition coefficient log P amounts to 
0.13 (3), which is comparable to that of, e.g., atenolol (log P, 0.2). The 
chemical structure of the drug is illustrated in Fig. 1. (4). 
The parmacokinetic profile of celiprolol shows two unusual and interest- 
ing characteristics. The plasma concentration-time curve frequency exhibits 
two peaks, and the bioavailability is low and increases with dose (5). The 
drug is not metabolized to any significant extent and is eliminated equally 
via urine and bile. Nonlinear increase in bioavailability after oral drug 
administration has been reported for other drugs like penicillamine (6), as 
well as pafenolol (7,8) and nadolol (9), which exhibit a similar pharmaco- 
kinetic profile as celiprolol. These observations appear to be very complex 
in origin, since they could be due to limited liver extraction capacity, satu- 
rable renal excretion, or a dose-dependent uptake from the gastrointestinal 
tract. However, since celiprolol shows dose linearity after intravenous (iv) 
administration in humans (10) as well as in preliminary dog studies (data 
not shown), and since a dose-dependence of the terminal half-life was neither 
detected following iv nor following po dosage in dogs, a nonlinear absorp- 
tion process appears to be the most likely explanation. 
Nadolol has been shown to form stable micellar complexes with bile 
salts, which leads to a decrease in thermodynamic activity and, therefore, 
to an increased oral clearance and bioavailability with low doses (11,12). 
Lennern/is and Regardh (13) proposed the same mechanism for pafenolol. 
Furthermore, they regarded bile salt complexation as a possible explanation 
for the occurrence of double peaks. Since bile salts are actively reabsorbed 
in the distal ileum, the drug may be released from the complex due to 
HsC,,,~O OH 
I I H Ca, ~,~'~,~O~N,,,~CHs 
L,~ CHa H 
FIG. 1. Chemical structure of celiprolol (* chiral centre). 
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equilibrium reaction and thereafter be absorbed, leading to a second peak 
in the plasma concentration-time profile. 
Another hypothesis for explaining the double-peak phenomenon is 
gastric emptying-limited absorption kinetics. In general, the main factors 
influencing drug absorption include the rate of disintegration of the dosage 
form, the dissolution rate, and the intestinal wall permeability of the com- 
pound (14). For drugs that are not restrained by any of the above factors, 
gastric emptying can become the rate-limiting step in absorption. During the 
fasted state the gastrointestinal tract shows a cyclic pattern of contractions, 
consisting of quiescent phases (Phase I) without contractions of 1 to 3 hr 
followed by active phases with intense contractions (Phase II/III) of about 
5-30 min. Gastric emptying is mainly associated with the active phase of 
the gastric cycle. Variations in gastric emptying pattern may therefore lead to 
variations in peak blood levels and times to peak. Furthermore, incomplete 
emptying either during the initial first-order emptying or the first active 
phase could result in a two-phase absorption with a portion of the drug 
remaining in the stomach until the next active phase occurs. 
Double or multiple peaks in the concentration-time profile and/or  vari- 
ations in the invasion profile have been reported for a series of drugs includ- 
ing acetaminophen (15), cimetidine (16), ranitidine (17), furosemide (18), 
flurbiprofen (19), pafenolol (20), veralapride (21), ciclotropium (22), etac- 
rynic acid (23), ibuprofen (24), tranylcypromine (25), and celiprolol (26). 
However, in only a few cases the available data could provide an explanation. 
Flurbiprofen, for example, has shown to be most likely gastric emptying 
controlled in its absorption profile (19). Recent studies by Artursson et  al. 
(27) in Caco-2 cells suggest that an active intestinal secretion (exsorption) 
of celiprolol in the proximal part of the intestine could be responsible for 
the nonlinear bioavailability. These authors hypothesized that this kinetic 
process may as well be a causative factor for the double peaks. Facing this 
variety of hypotheses, a thorough investigation of the absorption mechanism 
of celiprolol is therefore necessary to explain nonlinear bioavailability and 
double-peak phenomenon. 
MATERIALS AND METHODS 
D o g  Studies 
Four dogs (two female mongrels, one male and one female beagle) were 
included in the present study. Prior to each experiment, the dogs were fasted 
for 18 hr with free access to water. 
Recordings of the gastric motor activity were obtained using a 
pneumohydraulic manometric system, which consisted of a flexible catheter 
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FIG. 2. Placement of the multilumen catheter in the stomach and representative 
fasted-state motility cycle 
containing six motility probes. After swallowing of the oral catheter by the 
dog, at least two recording sites were placed in the proximal and distal 
antrum. Distilled water was infused through these ports at a rate of 1.5 ml/ 
min. Stomach contractions interrupted the water flow by closing the open- 
ings in the catheter, resulting in a back pressure along the tube (Fig. 2.). 
Strain gauge transducers transformed the intraluminal pressure into electri- 
cal signals, which were then printed on a chart recorder and saved on a 
computer for further analysis. 
Motility was recorded continuously for 4 hr after drug administration. 
Oral doses of 150 mg racemic celiprolol in 30 ml water were given as a 
solution in a crossover design during four different phases of the gastric 
cycle: early Phase I, middle of Phase I, late Phase I, and Phase III. Intra- 
venous doses of 50 mg racemic celiprolol were also given to obtain disposi- 
tion and bioavailability parameters. Blood samples were obtained from an 
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indwelling heparin lock catheter, which was placed in the cephalic vein of 
the front leg, prior to dosing and 15, 30, 45, 60, 75, 90, 120, 150, 180, 240, 
300, and 360 min after dosing for the po study and prior to dosing and 2, 
5, 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, and 360 min after dosing 
for the iv study. The samples were centrifuged and stored at -20~ until 
analyzed. 
Analytical Methods 
Plasma samples were analyzed using a enantiospecific HPLC assay 
described previously (2). 
Data Analysis 
Noncompartmental analysis was performed employing standard defini- 
tions and calculation procedures. The motility data were analyzed utilizing 
STATISTICA (release 4. l). 
Population pharmacokinetic parameters were obtained with a two- 
compartment open model that included two input (depot) compartments 
with two lag times, into which the gastrointestinal motility data were 
incorporated (Fig. 3). The first depot compartment represents the fraction 
of the dose that is emptied into the intestine with occurrence of the first 
Phase II/III of the gastric cycle. With the following Phase II/III, the remain- 
ing portion of the dose (in the second depot compartment) is released from 
T ~ ( 1 ) + T M ( 1 )  
_ K ~  
FIG. 3. The two-compartment open model incorporating gastric motility data and 
two lag times for different dose fractions. (Lag = total lag time following po dos- 
age= Tabs+ T III; T III: time to onset of Phase II /III ;  Tabs: effective absorption 
lag time for celiprolol from the intestine into the systemic circulation.) 
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the stomach. In both cases, a lag time is observed that may be divided into 
the time to Phase II/III (T III), assuming this is the time when the drug is 
emptied from the stomach, and the time to absorption (Tabs). The rationale 
for incorporating the time to Phase III into the model was to reduce the 
variability in the onset of absorption, which was due to variable gastric 
emptying. Therefore, the parameter to be estimated was not the lag time 
but the actual absorption time (Tabs) required for the drug to enter the 
central compartment after leaving the stomach. Thus, two bioavailability 
fractions, F1 + F2, are obtained from the two absorption events. The central 
compartment represents the blood, whereas the peripheral compartment 
represents the tissue. The model is characterized by a set of first-order linear 
differential equations 
dA=o for t<  T i l l  (1) 
dt 
dAl = -kal  x A1 for t>  T i l l  (1) 
dt 
dA2 = -ka2 • A2 for t>  Ti l l  (2) 
dt 
dA3 =kal x A1 +ka2 x A2 -k34 x A3 +k43 x A 4 -  k30 x A3 
dt 
dA4=k34 x A3 -k43  • A4 
dt 
where kal and ka2 are the rate constants for the drug entering the central 
compartment after lag time 1 and lag time 2, respectively. The distribution 
into the peripheral compartment is represented by k34, and the velocity for 
redistribution into the central compartment is determined by k43. The rate 
constant for elimination from the central compartment is k30. A1, .42, A3, 
and .44 are the amounts of drug in the depot compartments 1 and 2, central 
compartment 3, and peripheral compartment 4, respectively. The parameters 
to be estimated employing this model are kal, ka2, ka4, k43, k3o, tabst, tabs2, 
FI, and F2. Additionally, the volume of the central compartment (V3) has 
to be estimated in order to convert blood concentrations into amounts in 
the four compartments. The computer program NONMEM 77 Version IV 
Level 1 (written in ANSI FORTRAN 77) was used to estimate the pharma- 
cokinetic parameters. NONMEM (Non-linear Mixed Effects Model) is 
designed to fit general statistical (nonlinear) regression type models to data 
(28), offering two major advantages when compared to other nonlinear 
regression programs: first, it is able to incorporate fixed effects, mainly 
physiological parameters that vary among subjects, into the pharmacokinetic 
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model. Second, it can pool data simultaneously from different individuals. 
Intraindividual and interindividual variations can therefore be separated and 
quantified. 
Data from the four dogs obtained in the study described above were 
analyzed. The total set of data contained four iv studies and 16 po studies. 
In the first step, the model parameters were fitted to the individual iv data 
sets, subsequently, each po set was modeled simultaneously with the corre- 
sponding iv data, resulting in an individual fit of all po and iv data within one 
dog. Intraindividual variability was obtained from the difference between the 
predicted and the observed data. Finally, parameters of the individual model 
were fitted to the complete data set. 
After incorporating population error parameters for bioavailabitity into 
the model, the four iv data sets and subsequently the entire data pool were 
fitted to obtain the average pharmacokinetic profile and the interindividual 
error. Although a limited data set of 20 experiments was analyzed by the 
NONMEM, which might be somewhat small to be considered a population, 
the NONMEM terminology for the population parameters is used 
throughout the rest of the manuscript. 
RESULTS 
In the dog only Phase I (quiescent phase) and Phase II/III (active 
phase) of the gastric cycle can be clearly distinguished, with mean values 
for the duration of the two phases being 57.2 + 8.2 and 19.4 4-4.5 rain, respec- 
tively (Fig. 4). These time frames are in good agreement with data obtained 
employing electrical measurement of the action potentials in dogs (29), as 
well as with data reported for humans (30). 
Examples of two individual plasma profiles, dosed in the quiescent 
phase, together with the corresponding motility data are shown in Fig. 5(a 
and b). Significant lag times were observed with all experiments where the 
drug was administered in Phase I, suggesting that celiprolol is not absorbed 
from the stomach and can only reach the absorption site after gastric empty- 
ing has taken place. Highest variations among the lag times were observed 
when the drug was administered during the early quiescent phase, since 
the emptying of celiprolol depends on the timing of dosing relative to the 
occurrence of the next active phase (Fig. 6a). Variations in the intravenous 
data are relatively small by comparison (Fig. 6b), suggesting that varying 
factors during the absorption process determine the variability in the oral 
pharmacokinetic profile of celiprolol. Biphasic absorption, resulting in dou- 
ble peaks or shouldering in the plasma concentration-time profile, was usu- 
ally observed when the duration of the active phase was relatively short 
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FIG. 4. The duration of the different phases of the gastric cycle in the fasted state for four 
dogs. 
(<  10-15 min). An excellent correlation ( r= .97) was obtained between the 
time to gastric emptying and the time to peak concentration (including the 
time-to the second active phase when an additional plasma peak was 
observed), showing a linear relationship with a slope close to 1 (Fig. 7). 
Therefore, the intercept of the correlation line (b=0.55 hr) may be inter- 
preted as the actual absorption time, needed for the drug to enter the sys- 
temic circulation after reaching the intestine. The double-peak frequency 
observed was approximately 75% when all data sets showing either a clearly 
pronounced second peak or shouldering in the concentration-time profile 
(that was above the assay precision limit) were included. 
Interestingly, bioavailability was significantly increased and less variable 
when celiprolol was administered during Phase II/III (Fig. 8). This is most 
likely due to the better mixing effect in the intestine and/or less dilution by 
the gastrointestinal fluids and the water infused by the motility equipment. 
The resulting mean pharmacokinetic parameters from four studies in each 
dog, given in Table I, confirm again the high inter- and intrasubject vari- 
ability regarding t . . . .  Cmax, and bioavailability. However, due to the strong 
correlation between time to Phase III and t . . . .  gastric emptying can explain 
the variations in the time to the onset of absorption. Peak concentration 
and rate of absorption may still vary, especially when the drug is dosed in 
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FIG. 5. Plasma concentration-time profile of 150 mg racemic celiprolol-HCl po dosed 
in (a) early Phase I, (b) middle of Phase I with the corresponding motility data (dosed 
circles = S-celiprolol, open circles = R-eeliprolol). 
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FIG. 6. Mean plasma concentration-time profiles of (a) 150 mg racemic celiprolol- 
HC1 dosed orally in early Phase I (n=4) and (b) 50 mg racemic celiprolol-HCI after 
intravenous administration (n =4). 
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FIG. 7. Correlation between time to Phase II/III (=time period between dosing and 
Phase II/III onset) and time to peak concentration of S-celiprolol (n = 16) (correla- 
tion was obtained by linear regression analysis). 
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FIG. 8. Bioavailability of S-celiproloi following administration in different motility 
phases. 
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Table I. Pharmacokinetic Parameters from Four Dogs (Noncompartmental Analysis) ~ 
Parameter Enanfiomer Dog A Dog B Dog C Dog D 
Cma~(pg/mi) S i .494- 0.24 1.53 + 0.25 2.01 + 0.49 1.92 + 0.54 
R 1.54 + 0.23 1.54 + 0.24 2.05 + 0.49 1.95 + 0.54 
t,~a~(hr) S 0.814-0.38 1.56=t= 1.01 0.94:t=0.38 1.065=0.43 
R 0.81 +0.38 1.564- 1.01 0.945=0.38 1.065=0.43 
AUC(I, tg* hr/ml) S 2.905=0.51 3.945=0.84 4.095=0.29 4.545=0.76 
R 3.115=0.64 4.065=0.87 4.595=0.40 5.025=0.78 
AUMC(p.g* hr2/ml) S 9.975=1.83 6.184-2.5 14.255=2,03 17.625=4.49 
R 10.974-3.07 16.78+2.1 17.435=2.88 21.454-5.97 
ke,(hr-' ) S 0.314-0.03 0.334-0.06 0.305=0.04 0.294-0.05 
R 0.305=0.04 0.324-0.05 0.284-0.05 0.264-0.05 
t ,n(hr)  S 2.29 • 0.23 2.18 • 0.40 2.394- 0.32 2.46 • 0.42 
R 2.304-0.29 2.244-0.37 2.584-0.42 2.724-0.54 
MRT(hr) S 3.434-0.21 4.16• 3.48+0.34 3.894-0.85 
R 3.48+0.48 4.22+0.54 3.784-0.34 4.254-1.03 
MAT(hr) S 1.275=0.21 2.074-0.62 1.164-0.34 0.87+0.79 
R 1.385=0.48 2.135=0.54 1.245=0.35 1.294-1.03 
CL(I/hr) S 26.374-4.07 19.654-3.88 18.41 4- 1.32 16.91 4-2.82 
R 24.984-5.97 19.174-4.07 16.434-1.42 15.234-2.43 
Vdls(l) S 59.414-8.55 34.51+8.01 53.934-13.1 40.424-5.78 
R 59.99+7.51 36.954-6.52 50.944-7.29 45.924-7.27 
Bioavailability(%) S 68.584- 12.07 62.654- 13.39 74.904-5.28 73.404-12.28 
R 73.534-15.13 61.734-13.3 79.604-6.97 75.084-11.73 
~Mean4-SD from four po treatments with 150 mg racemic celiprolol-HCl as a solution. 
the quiescent phase, because of concentration differences depending on the 
time to Phase II/III due to dilution as mentioned earlier. Differences in drug 
concentration might also explain the variations in bioavailability (45-90%), 
which could reflect active intestinal secretion or an interaction with bile salts. 
The average individual pharmacokinetic parameters, the mean param- 
eters for all four dogs, and the average population pharmacokinetic param- 
eters estimated by NONMEM are given in Table II. Individual fits for iv 
and po data are shown in Fig. 9(a and b), supporting the ability of the two- 
phase absorption model to predict lag times and multiple peaks in the plasma 
concentration-time profile of celiprolol in dogs, when the motility param- 
eters are known. 
In the first step, the parameters of the model were fitted simultaneously 
to four sets of oral data combined with the corresponding intravenous data. 
The values for the pharmacokinetic parameters within one dog, as well as 
the mean values for all four dogs were acceptably tight. The standard errors 
for the parameter estimates amounted to 10-20% for the individuals and 
10-30% for the mean values. Especially, the initial absorption rate constant 
with 2.8 + 12 hr- '  was surprisingly low in its variation considering the small 
number of sample points (n = 2-4) during the absorption phase. The mean 
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Table Ii. NONMEM Pharmacokinetic Parameter Estimates of the Individual and Population 
Analysis of S-Celiprolol (n =4) 
Dog A Dog B Dog C Dog D Mean Population 
Ka,(hr-' ) 3.1 • 
Ka2(hr -1 ) 0.674-0.57 
K34(hr-" ) 4.64-0.67 
K43(hr -I ) 1.04-0.16 
K30(hr- ' ) 2.644-0.31 
V(L) 7.26• 
tab,,(hr) 0.074-0.01 
F1 0.63 4- 0.04 
tab,2(hr) 
F2 0.11 4-0.04 
MVO/'  -298.1 
2.56:t:0.42 2.73-t-0.45 2.94-00.9 2.84-0.12 2.544-0.35 
0.334-0.2 0.31 +0.12 0.234-0.69 0.45-1-0.1 0.234-0.04 
12.8• 7.014-0.79 9.854-3.79 8.57-1-1.77 9.33-t-1.07 
1.96:s 1.36+0.18 i.934-0.94 1.534-0.23 2.14-0.21 
5.37+0.52 3.054-0.25 3.994-0.81 3.754-0.61 4.464-0.31 
2.38• 5.064-0.51 4.26+1.02 4.71+1.01 4.054-0.68 
0.44• 0.1 • 0.37-1-0.05 0.24• 0.13• 
0.474-0.03 0.76• 0.74• 0.654-0.07 0.734-0.07 
0.86:t:0.05 0.97-1-0.12 0.844-0.05 0.58• 0.434-0.03 
0.21 4-0.1 0.074-0.01 0.264-0.05 0.154-0.04 0.094-0.01 
-151.51 -188.26 -111.17 -187.26 -596.30 
a All values are means q-SE. 
b Minimum value of objective function. 
bioavailability (F1 +F2) from the individual analysis was 0.8 4-0.11, which 
was in good agreement with data obtained from the noncompartmental 
analysis with 0.7 +0.03 (Table 1). 
In the second step, 4 iv data sets and subsequently 16 sets of oral data 
together with the four corresponding intravenous data sets were analyzed 
in the population model. Figure 10a shows the NONMEM population fit 
for the iv data and Fig. 10b the population fit of the entire data pool. In 
most cases, the population pharmacokinetic parameter estimates exhibit less 
variability than the mean values from the individual analysis (Table II). This 
is due to the ability of NONMEM to evaluate intrasubject and intersubject 
variations simultaneously. The individual analysis considers only intra- 
subject variations, therefore resulting in mean values from this step that are 
less precise than the population parameter estimates. Furthermore, the larger 
number of data points in the population analysis provides NONMEM with 
more information to obtain accurate estimates. The goodness-of-fit from the 
estimation step is represented by the minimum value of objective function 
(M VOF), which is comparable to the sum of squares in regression analysis. 
A drop in the MVOF reflects therefore an improvement of the model. The 
overall population bioavailability estimated (F1 + F2) was 0.82 + 0.08, which 
was in good agreement with the average individual bioavailability estimated 
in four dogs (0.8 4-0.11). Approximately 10% of the orally available dose 
was assigned to the second peak when the entire data pool of 16 po experi- 
ments was taken into consideration. Intrasubject variability was calculated 
to be 17%, and the interindividual variability for bioavailability was found 
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FIG. 9. NONMEM individual fit of (a) iv data of S-eeliprolol (Dog B) and (b) po 
data with a double peak (Dog B). 
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after dosing. 
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DISCUSSION 
When compared to human data described earlier (3), in the dog, the 
first peak in the plasma concentration-time profile was more pronounced 
than the second one and the first input rate constant was about 5 to 10 
times higher than the second one. Lower input rates for the second absorp- 
tion phase may reflect the concentration-dependent uptake of celiprolol, 
since the drug solution undergoes dilution in the stomach, and/or  might be 
due to the less frequent sampling time during that part of the study. The 
differences in the peak ratios could be explained by the fact that celiprolol 
was adminstered as a Solution in the present study, whereas it was given as 
a tablet (celiprolol 200 mg, Selectol ~) in the human studies (3). Administra- 
t ionof  a solid dosage form in the fasted state may result in a partial emptying 
of dissolved or suspended drug particles, Thus, for the remaining part of 
the tablet, a passage of another active phase is required, so that the second 
portion of the dose reaches the absorption site. Or parts of the dose might 
even remain in the stomach during a short active phase, and only be emptied 
with the occurrence of the following Phase II/III. Similar observations were 
reported in a flurbiprofen study (19), where the rate and extent of absorption 
during the first phase decreased when the drug was given as a tablet, and 
almost 70% of the total drug absorption was associated with the second 
absorption phase. Furthermore, in all clinical studies with celiprolol the 
subjects had ingested a meal 0.5-3 hr aftter drug intake, which terminates 
cyclic gastric emptying for various lengths of time and makes a comparison 
between the data even more difficult. 
The double-peak pattern observed in the dog is most likely due to gastric 
emptying. This is further supported by the observation that the plasma half- 
life in dogs (2-2.5 hr) is shorter than in humans (4-5 hr), which makes the 
influence of gastric emptying as the rate-limiting step for absorption more 
apparent. Simulation studies have shown that an increase in the predominant 
elimination rate constant results in a significant increase in the frequency of 
double peaks (31). Amidon et al. tried to provide an additional explanation 
for the discontinuous plasma profile of cimetidine by taking the intestinal 
transit rate into consideration. They concluded that dosing time relative to 
phasic activity together with variability in flow rate out of the stomach are 
crucial to the occurrence of double peaks (16,31). Biphasic gastric emptying 
was also shown to be one causative factor of the double-peak behaviour for 
acetaminophen (15). 
The increased bioavailability of celiprolol when the drug was adminis- 
tered during Phase II /III  of the gastrointestinal cycle could be a function 
of increased bile salt levels in the intestine due to gallbladder-emptying dur- 
ing Phase II / III  (32). However, for 13-blockers there is evidence for a decrease 
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in absorption in the presence of bile salts due to formation of insoluble 
complexes as reported for nadolol and pafenolol (32,33), but absorption 
studies with celiprolol in rats with and without bile salts performed by our 
group did not show any evidence for this interaction (data not shown). 
Furthermore, for most drugs bile salts function as solubilization enhancers, 
but since celiprolol exhibits very high aqueous solubility, no major effect is 
expected from the presence of bile salts. The contribution of bile to the 
increased absorption in Phase II/III appears therefore to be of minor import- 
ance. An increase in transit time might lead to an increased rate of absorption 
due to more rapid gastric emptying as well as a decrease in extent of absorp- 
tion as a consequence of reduced contact time with the small intestinal 
surface area. For celiprolol a decrease in time to gastric emptying might in 
part contribute to the increased bioavailability. Although data showing the 
actual mechanism of this observation is not readily available yet, the most 
likely explanation appears to be that differences in intestinal concentration 
of celiprolol caused by more rapid gastric emptying and less dilution by 
the gastrointestinal fluids account for the increased bioavailability, since 
celiprolol exhibits nonlinear increase in oral absorption with increasing 
doses. 
With respect to the population model, fitting the data to the two- 
compartment model with two lag times without incorporating the parameter 
"time to Phase III" resulted in an unsuccessful minimization, because the 
second absorption phase was not appropriately fitted anymore. The gastro- 
intestinal motility data, incorporated as a covariant for the lag time into the 
population pharmacokinetic model, therefore improves the precision of the 
plasma concentration predictions significantly. 
In conclusion, the two-absorption phase open model incorporating 
intestinal motility data was shown to be appropriate in predicting bimodal 
plasma concentration-time profiles of celiprolol. The observed double-peak 
phenomenon in dogs is most likely due to variations in gastric emptying. 
However, the shape and frequency of the double peaks of celiprolol in dogs 
differ from data obtained in humans, which was also observed for cimetidine 
(34). Therefore, secretion of celiproiol into the intestinal lumen (27,35) 
mediated by membrane-bound p-glycoprotein or a proton/cation trans- 
porter might play a role with regard to double-peak formation and 
nonlinear bioavailability. Saturation of the transport system with high 
drug concentrations would result in enhanced absorption and, therefore, 
increased bioavailability. Assuming a site-specific location of the transport 
system in the proximal intestine, a second absorption phase might occur 
in the lower intestine, leading to a second peak in the plasma profile. 
Very recent studies in Caco-2 cells as well as clinical studies with talinolol, 
a I~-blocker structurally close to celiprolol, performed by Wetterich et al. 
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(36) have shown fur ther  evidence for this class of  c o m p o u n d s  being actively 
secreted in to  the intestine. 
Hence,  the origin of  the var ia t ions  in h u m a n  da ta  might  be more  com- 
plex and  only  in par t  be explained by the gastrointest inal  moti l i ty  pat terns.  
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